Compare CDMOs with cardiovascular drug manufacturing expertise for antihypertensives, anticoagulants, antiarrhythmics, and lipid-lowering therapies. Filter by dosage form, scale, and regulatory approvals.
170 companies listed
Cardiovascular drugs represent one of the largest established therapeutic segments, with a mature generics market and growing biologics pipeline. Manufacturing spans small molecule APIs (statins, ACE inhibitors, beta-blockers, calcium channel blockers), controlled-release oral solid dosage forms, and an expanding portfolio of injectable biologics (PCSK9 inhibitors, anti-inflammatory antibodies for atherosclerosis).
Formulation complexity is increasing. Many cardiovascular drugs require modified-release profiles to maintain therapeutic levels over 24 hours with once-daily dosing. Fixed-dose combinations (e.g., statin + antihypertensive) add formulation challenges around drug-drug compatibility, stability, and dissolution profile matching. CDMOs with strong oral solid dose and coating capabilities are well positioned.
Scale matters in this segment. Cardiovascular drugs often reach blockbuster commercial volumes -- hundreds of millions of doses per year. CDMOs need high-throughput tableting lines, efficient coating systems, and robust supply chain management to handle these volumes reliably. Ask about batch success rates and on-time delivery metrics for commercial-scale programs.
Canada
JAMP Pharma Group is a leading Canadian pharmaceutical company with over 35 years in the industry, active across generic drugs (JAMP Pharma), biosimilars (BioJAMP), branded products (Orimed Pharma), natural health products (Wampole/Laboratoire Suisse), and beauty products (Cosmetic Import). The company acquired a pharmaceutical manufacturing facility in Levis, Quebec, and manufactures prescription drugs in Canada through its JAMP Pharma Manufacturing division.
South Korea
Jeil Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company headquartered in Seoul that offers APIs, finished dosage products, and CMO services. The company has a production capacity of 1.5 billion oral dosage units per year and manufactures tablets, transdermal patches, and other dosage forms. Jeil supplies 62 products including APIs, excipients, and intermediates and is FDA-registered.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.